Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review
- PMID: 28761574
- PMCID: PMC5522984
- DOI: 10.1016/j.curtheres.2017.01.007
Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review
Abstract
Background: The Ebola virus has been responsible for numerous outbreaks since the 1970s, with the most recent outbreak taking place between 2014 and 2016 and causing an international public health emergency. Ebola virus disease (EVD) has a high mortality rate and no approved targeted treatment exists to date. A number of established drugs are being considered as potential therapeutic agents for the treatment of EVD.
Objective: We aimed to identify potential drug repositioning candidates and to assess the scientific evidence available on their efficacy.
Methods: We conducted a systematic literature search in MEDLINE, Embase, and other relevant trial registry platforms for studies published between January 1976 and January 2017. We included drug screening, preclinical studies, and clinical studies on repurposed drugs for the treatment of EVD. The risk of bias for animal studies and nonrandomized clinical studies was assessed. The quality of reporting for case series and case reports was evaluated. Finally, we selected drugs approved by established regulatory authorities, which have positive in vitro study outcomes and at least one additional animal or clinical trial.
Results: We identified 3301 publications, of which 37 studies fulfilled our inclusion criteria. Studies were highly heterogeneous in terms of study type, methodology, and intervention. The risk of bias was high for 13 out of 14 animal studies. We selected 11 drugs with potential anti-EVD therapeutic effects and summarized their evidence.
Conclusions: Several established drugs may have therapeutic effects on EVD, but the quality and quantity of current scientific evidence is lacking. This review highlights the need for well-designed and conducted preclinical and clinical research to establish the efficacy of potential repurposed drugs against EVD.
Keywords: chemoembolization; hepatic tumor; liver abscess.
Figures
Similar articles
-
Repurposed therapeutic agents targeting the Ebola virus: a protocol for a systematic review.Syst Rev. 2015 Nov 25;4:171. doi: 10.1186/s13643-015-0153-9. Syst Rev. 2015. PMID: 26607658 Free PMC article.
-
The effect of Ebola virus disease on maternal health service utilisation and perinatal outcomes in West Africa: a systematic review.Reprod Health. 2022 Feb 4;19(1):35. doi: 10.1186/s12978-022-01343-8. Reprod Health. 2022. PMID: 35120540 Free PMC article.
-
Assessing the Concepts and Designs of 58 Mobile Apps for the Management of the 2014-2015 West Africa Ebola Outbreak: Systematic Review.JMIR Public Health Surveill. 2018 Oct 29;4(4):e68. doi: 10.2196/publichealth.9015. JMIR Public Health Surveill. 2018. PMID: 30373727 Free PMC article. Review.
-
Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.PLoS Med. 2016 Mar 1;13(3):e1001967. doi: 10.1371/journal.pmed.1001967. eCollection 2016 Mar. PLoS Med. 2016. PMID: 26930627 Free PMC article. Clinical Trial.
-
Treatment of ebola virus disease.Pharmacotherapy. 2015 Jan;35(1):43-53. doi: 10.1002/phar.1545. Pharmacotherapy. 2015. PMID: 25630412 Review.
Cited by
-
A Systematic Review of Computational Drug Discovery, Development, and Repurposing for Ebola Virus Disease Treatment.Molecules. 2017 Oct 20;22(10):1777. doi: 10.3390/molecules22101777. Molecules. 2017. PMID: 29053626 Free PMC article.
-
Repurposing therapeutic agents and herbal medicines to defeat viral nemesis.Drug Dev Res. 2020 Sep;81(6):641-642. doi: 10.1002/ddr.21668. Epub 2020 Mar 30. Drug Dev Res. 2020. PMID: 32227604 Free PMC article. No abstract available.
-
Antiviral Therapy of COVID-19.Int J Mol Sci. 2023 May 16;24(10):8867. doi: 10.3390/ijms24108867. Int J Mol Sci. 2023. PMID: 37240213 Free PMC article. Review.
-
The Therapeutic Effect of Traditional Chinese Medicine on Inflammatory Diseases Caused by Virus, Especially on Those Caused by COVID-19.Front Pharmacol. 2021 May 26;12:650425. doi: 10.3389/fphar.2021.650425. eCollection 2021. Front Pharmacol. 2021. PMID: 34122073 Free PMC article. Review.
-
Antiviral options and therapeutics against influenza: history, latest developments and future prospects.Front Cell Infect Microbiol. 2023 Nov 29;13:1269344. doi: 10.3389/fcimb.2023.1269344. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 38094741 Free PMC article. Review.
References
-
- Changula K., Kajihara M., Mweene A.S., Takada A. Ebola and Marburg virus diseases in Africa: Increased risk of outbreaks in previously unaffected areas? Vol. 58, Microbiology and Immunology. Centers for Disease Control and Prevention. 2014:483–491. - PubMed
-
- Center for Disease Control and Prevention. 2014 Ebola Outbreak in West Africa - Case Counts [Internet]. 2014 [cited 2016 Sep 15]. Available from: http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/case-counts.html
-
- WHO. WHO Statement on the 1st meeting of the IHR Emergency Committee on the 2014 Ebola outbreak in West Africa [Internet]. 2014 [cited 2016 Sep 15]. Available from: http://www.who.int/mediacentre/news/statements/2014/ebola-20140808/en/
-
- WHO. New Ebola cases confirmed in Guinea as WHO warns of more possible flare ups [Internet]. 2016 [cited 2016 Sep 15]. Available from: http://who.int/csr/disease/ebola/new-ebola-cases-confirmed-guinea/en/
LinkOut - more resources
Full Text Sources
Other Literature Sources